Table 1.
Patient characteristics. Data presented as medians with interquartile ranges in parentheses or frequency with percentages in parentheses, using Fisher's exact test or Wilcoxon rank sum test, respectively.
| Characteristics | No Downgrade n=1202 (91%) |
Downgrade n=115 (9%) |
p-value |
|---|---|---|---|
| Age at Treatment (years) | 61 (56, 66) | 60 (55, 64) | 0.11 |
| Body Mass Index (kg/m2) (n=1316) | 28 (26, 31) | 27 (25, 30) | 0.007 |
| Clinical Stage (n=1314) | 0.017 | ||
| T1c | 784 (65%) | 90 (78%) | |
| T2 | 387 (32%) | 22 (19%) | |
| T3 | 27 (2.3%) | 3 (2.6%) | |
| T4 | 1 (0.1%) | 0 (0%) | |
| Total PSA (ng/mL) | 5.3 (4.0, 7.3) | 4.8 (3.1, 6.2) | 0.004 |
| Prostate Volume (cm3) | 32.3 (24.9, 44.6) | 34.4 (27.7, 51.8) | 0.014 |
| PSA Density (ng/mL per cm3) | 0.16 (0.11, 0.24) | 0.12 (0.09, 0.16) | <0.0001 |
| Percent of Positive Cancer Cores out of all Biopsy Cores (%) | 31 (17, 46) | 25 (13, 42) | 0.003 |
| Percent of Positive Cancer Cores with Gleason Pattern 4 Cancer out of all Biopsy Cores (%) | 16 (8, 25) | 8 (7, 15) | <0.0001 |
| Maximum Percent of Cancer involvement within a Positive Core with Gleason Pattern 4 Cancer (%) | 40 (20, 65) | 20 (10, 35) | <0.0001 |
| Seminal Vesical Invasion | 57 (4.7%) | 0 (0%) | 0.008 |
| Lymph Node Invasion (n=1279) | 46 (3.9%) | 0 (0%) | 0.029 |
| Positive Surgical Margin (n=1316) | 185 (15%) | 7 (6.1%) | 0.005 |
| Extracapsular Extension | 478 (40%) | 15 (13%) | <0.0001 |
| Pathologic Stage | <0.0001 | ||
| pT0 | 0 (0%) | 1 (0.9%) | |
| pT2 | 711 (59%) | 99 (86%) | |
| pT3 | 485 (40%) | 15 (13%) | |
| pT4 | 6 (0.5%) | 0 (0%) |
PSA indicates prostate-specific antigen.